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ABL gene translocations create constitutively active tyrosine
kinases that are causative in chronic myeloid leukemia, acute
lymphocytic leukemia and other hematopoietic malignancies.
Consistent retention of ABL SH3/SH2 autoinhibitory domains,
however, suggests that these leukemogenic tyrosine kinase
fusion proteins remain subject to regulation. We resolve this
paradox, demonstrating that BCR-ABL1 kinase activity is
regulated by RIN1, an ABL SH3/SH2 binding protein. BCR-
ABL1 activity was increased by RIN1 overexpression and
decreased by RIN1 silencing. Moreover, Rin1
 /  bone marrow
cells were not transformed by BCR-ABL1, ETV6-ABL1 or BCR-
ABL1
T315I, a patient-derived drug-resistant mutant, as judged by
growth factor independence. Rescue by ectopic RIN1 veriﬁed a
cell autonomous mechanism of collaboration with BCR-ABL1
during transformation. Sensitivity to the ABL kinase inhibitor
imatinib was increased by RIN1 silencing, consistent with RIN1
stabilization of an activated BCR-ABL1 conformation having
reduced drug afﬁnity. The dependence on activation by RIN1 to
unleash full catalytic and cell transformation potential reveals a
previously unknown vulnerability that could be exploited for
treatment of leukemic cases driven by ABL translocations. The
ﬁndings suggest that RIN1 targeting could be efﬁcacious for
imatinib-resistant disease and might complement ABL kinase
inhibitors in ﬁrst-line therapy.
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Introduction
Chromosome translocations that join the BCR and ABL1 (a. k.a.
c-Abl) genes give rise to BCR-ABL1 fusion proteins that are
causative in virtually all cases of chronic myeloid leukemia
(CML), in many cases of acute lymphocytic leukemia (ALL) and
occasionally in other myeloproliferative disorders (reviewed
in
1). In addition, ETV6 (a.k.a. TEL) forms fusion oncogenes with
ABL1
2 and the closely related ABL2 (a.k.a. Arg)
3 in some
leukemias. ABL proteins are non-receptor tyrosine kinases that
are normally under tight regulation, but BCR-ABL1 fusions are
constitutively active. The ABL kinase inhibitor imatinib mesylate
(a.k.a. STI571 or Gleevec) is a highly effective treatment for CML
(reviewed in
4), demonstrating that drugs directly targeted to
oncoproteins can be used to manage cancer and perhaps
eventually be part of a curative therapy.
Unfortunately, some leukemias with activated ABL oncopro-
teins do not respond to imatinib. For CML patients who do
respond, there is a signiﬁcant risk of developing resistance
because of strong selective pressure for BCR-ABL1 kinase
domain mutations that block inhibitor action but retain the
catalytic function of the oncoprotein.
5 Second-generation kinase
inhibitors offer hope for combating imatinib resistance, with
some drugs successfully targeting the highly refractory BCR-
ABL1
T315I mutant.
6 But even these new catalytic site inhibitors
have limitations in their effectiveness during accelerated and
blast-phase CML, as well as in the treatment of other ABL fusion
leukemias including ALL. In addition, compound mutations
following sequential treatment of CML patients with multiple
kinase inhibitors
7 provide a path to broad resistance. Some
attempts have been made to circumvent resistance by reducing
BCR-ABL1 expression
8,9 or stability,
10,11 or by targeting
collaborative signaling pathways.
12–15 A more direct approach
for improving treatment would be to maintain focus on reducing
tyrosine kinase activity by targeting oncogenic ABL outside the
catalytic site.
ABL tyrosine kinases function in the cytoplasm to coordinate
actin remodeling, a function mediated by carboxy terminal
ﬁlamentous actin binding and bundling domains, and by the
tyrosine phosphorylation of multiple actin remodeling regulator
proteins. ABL1 also has nuclear DNA damage response
functions mediated by a DNA-binding domain and targeted
tyrosine phosphorylation. ABL activity is normally regulated at
multiple levels. An amino terminal myristoyl group can attach to
a surface pocket in the kinase domain, contributing to an
autoinhibitory fold,
16,17 and a short amino terminal ‘cap’ peptide
further stabilizes an inactive conformation through additional
surface interactions. Downstream of this peptide are SH3 and
SH2 domains that cradle the kinase domain and contri-
bute to the adoption of a less-active enzyme conformation.
18
In addition, several tyrosines in and around the ABL kinase
domain can be phosphorylated in trans (by ABL itself and by
SRC family kinases), leading to increased catalytic activity.
19–22
It appears that each form of regulation is conserved between
ABL1 and ABL2, which are more than 90% identical throughout
their SH3, SH2 and kinase domains.
Chromosome translocations that give rise to BCR-ABL1 and
other ABL1 fusion oncogenes remove the ﬁrst coding exon of
ABL1. This eliminates both the myristoylation site and the amino
terminal ‘cap’ that participate in stabilizing the inactive
conformation, explaining in part the elevated and constitutive
kinase activity of the fusion protein. The same ABL breakpoint is
seen regardless of the BCR breakpoint, which is variable. Even
with fusion partners other than BCR, the ABL1 breakpoint
resides between the alternate ﬁrst exon (1b) and the second exon
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23 Moreover, oncogenic translocations involving ABL2,
although less common, show the same arrangement.
3 In
summary, except for extremely rare variants (reviewed in
24),
human ABL fusion oncoproteins are devoid of the autoinhibitory
cap peptide, but consistently retain ABL SH3 and SH2 domains
that provide a separate autoinhibitory function likely to limit
kinase activity.
25 In the murine retroviral v-Abl oncoprotein, by
contrast, the Abl1 SH3 domain is disrupted by fusion with viral
Gag sequences. As a result, v-Abl is a highly active kinase and
v-Abl is a more potent transforming gene than BCR-ABL1.
26
RIN1 is a RAS effector protein that binds to and activates ABL
tyrosine kinases.
27,28 Signaling is initiated by low-afﬁnity
binding of a proline-rich sequence on RIN1 to the SH3 domain
of ABL. This interaction leads to phosphorylation of RIN1 on
tyrosine 36, which subsequently associates with the ABL SH2
domain. The resulting stable divalent interaction (RIN1 proline-
rich motif and phospho-Tyr
36 bound to ABL SH3 and SH2
domains, respectively) relieves the ABL autoinhibitory fold and
leads to activation of the ABL kinase through enhanced catalytic
efﬁciency.
27 Both ABL1 and ABL2 are activated by RIN1, and
this requires only the ABL SH3, SH2 and kinase domains.
Activation by RIN1 is independent of ABL transphosphorylation
and is unaffected by an imatinib resistance mutation.
27 Silencing
of RIN1 results in less tyrosine phosphorylation on CRKL, one of
the best characterized ABL substrates, and deletion of the mouse
Rin1 (mRin1) gene causes reduction in basal levels of phospho-
CRKL.
28 These observations demonstrate that RIN1 directly
stimulates the tyrosine kinase activity of ABL proteins and is
required for maintaining normal ABL kinase activity in vivo.
We showed previously that RIN1 interacts with BCR-ABL1
and that overexpression of RIN1 promotes the transforming
ability of BCR-ABL1 in hematopoietic cells and can rescue low
transformation efﬁciency BCR-ABL1 mutants.
29 Moreover,
RIN1 signiﬁcantly enhanced the leukemogenic properties of
BCR-ABL1 in a murine model system.
29 These ﬁndings suggest
that the ‘constitutively active’ BCR-ABL1 oncoprotein remains
responsive to positive regulation by RIN1. Here we show that
BCR-ABL1-positive leukemia cell phosphotyrosine levels are
increased by RIN1 overexpression, providing an explanation for
leukemogenic enhancement by RIN1. Deletion of RIN1 blocked
transformation of bone marrow cells by multiple ABL fusion
oncogenes, including the kinase inhibitor-resistant mutant BCR-
ABL1
T315I, demonstrating the cell-autonomous dependence of
ABL oncoproteins on RIN1. Silencing of RIN1 in a BCR-ABL1-
positive leukemia cell line and primary ALL cells decreased
levels of cellular phosphotyrosine, and at the same time
increased sensitivity to imatinib. Our results demonstrate a vital
role for the physiological ABL regulator RIN1 in transformation
by BCR-ABL1, while uncovering a novel point of vulnerability
that could be exploited for treatment of leukemias driven by
ABL tyrosine kinase oncoproteins.
Materials and methods
Expression constructs
The MSCV retrovirus constructs expressing BCR-ABL1, BCR-
ABL1þRIN1
ABD, ETV6-ABL1 and v-Abl have been previously
described.
29 BCR-ABL1þRIN1
ABDmut was created by replacing
the EcoRI-ﬂanked fragment of wild-type (WT) RIN1
ABD with the
equivalent fragment from RIN1
ABDmut (also called ABD
28,29).
Note that RIN1
ABD was used instead of full-length RIN1 to avoid
the retrovirus size limit. The BCR-ABL1
T315I mutant retrovirus
was a generous gift from Charles Sawyers (Memorial Sloan
Kettering Cancer Center, New York, NY, USA). The RIN1-silencing
short hairpin RNA (shRNA) lentivirus in the pLKO.1-puro vector
and the scramble control lentivirus pLKO.1SCR-puro contain a
puromycin resistance gene and were obtained from Sigma Aldrich
(St Louis, MO, USA) (Mission shRNAs SHGLY-NM_004292 and
SHC002, respectively). The stability of RIN1 silencing in trans-
duced TOM-1 cells was validated by immunoblot (Supplementary
Figure S4B). mRin1 was expressed from an M4 lentivirus vector
30
containing a blasticidin resistance gene.
Cell culture reagents and conditions
Retroviruses and lentiviruses were produced in transfected
HEK293T cells, and concentrated stocks were created as
previously described.
28
The myeloid BCR-ABL1 leukemia cell lines KU-812 and
LAMA-84 (gifts of Brian Druker, Oregon Health and Science
Univ., Portland, OR, USA) and the B lymphoid BCR-ABL1
leukemia cell lines BV173 (gift of Brian Druker) and TOM-1 (gift
of Kathleen Sakamoto, UCLA) were grown in RPMI 1640 medium
with 10% fetal bovine serum (Hyclone, South Logan, UT, USA)
and 1% penicillin streptomycin (Invitrogen, Carlsbad, CA, USA;
# 15140). LAX2 cells are primary BCR-ABL1 pre-B ALL cells
obtained from the bone marrow biopsy of a 38-year-old patient
with relapse leukemia. LAX2 cells were propagated in sublethally
irradiated NOD/SCID mice and kept on OP9 stromal cells in
Minimal Essential Medium alpha with 20% fetal bovine serum.
Lentivirus infections were carried out using 5 10
4 cells or
1 10
7 cells for LAX2, and a 1:1 dilution of virus stock in 2X
RPMI medium for 12–16h at 371C. In some cases, infections
were carried out in wells coated with retronectin (Takara Bio Inc.,
Kyoto, Japan). Silencing shRNA-infected cells were selected using
puromycin (1mg/ml for LAX2 TOM-1, K562 and KCL22. mRin1-
infected cells were selected with blasticidin (5mg/ml).
Bone marrow cells were obtained from femurs and tibias
of C57Bl/6 mice (6–8 weeks old) using a standard protocol.
31
FACS analysis was performed in a blinded manner on WT and
Rin1
 /  bone marrow cells using a selection of antibodies
recognizing surface markers for B cells, T cells and granulocytes
(B220, CD43, BP-1, CD24, IgM, CD19, Kit, CD4, CD8,
Gr-1 and CD11b). Analysis of individual markers and Hardy
fractions
32 showed no signiﬁcant difference between WT
and mutant. Retrovirus infections were carried out as previously
described
29 using a multiplicity of infection range from 0.1
to 10. Titers were based on transduction efﬁciency of NIH3T3
cells (all viruses encode a GFP marker). Each multiplicity of
infection was based on minimum consistent transformation
of bone marrow cells, to adjust for some variation among
virus stock preparations. Infected cells were plated at a density
of 5 10
6 cells/well in six-well culture plates, with duplicate
wells for each sample. On the indicated days, cells were
resuspended and a sample was removed for Trypan blue
staining and counting of viable cells. After each count, half of
the culture from each well was discarded and replaced with
fresh medium.
For phosphotyrosine analysis of K562 cells expressing vector
control or RIN1 protein, cells were treated with the indicated
concentrations of imatinib for a total of 30min. Cells were
incubated at 371C for 15min, followed by addition of 10mM
phenylarsine oxide and incubated for another 15min. Cells
were lysed in RIPA buffer before immunoblot analysis.
Cell proliferation assays were performed after ﬁrst evaluating
the sensitivity of TOM-1 and LAX2 to a range of imatinib
concentrations. For TOM-1, 1 10
5 cells were cultured in 4ml
RPMIþ10% fetal bovine serumþPSG medium with or without
8mM imatinib. We used 8mM because it was the highest imatinib
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cells. For LAX2 cells, we used 10mM imatinib, which showed
moderate cytotoxic effects on these primary ALL cells expressing
BCR-ABL1
T315I. The BCR-ABL1 kinase domain of primary
PhþALL cells and cell lines was ampliﬁed and sequenced
using PCR primers as described.
33 On the indicated days, the
cells were resuspended and samples were removed for Trypan
blue staining and direct cell counting and for propidium iodide
staining and ﬂow cytometric analysis.
Immunoprecipitations, immunoblots and
immunohistochemistry
Immunoprecipitations were performed, as indicated, with poly-
clonal anti-RIN1 (BD Biosciences, San Jose, CA, USAFDiscon-
tinued) or polyclonal anti-CRKL (Santa Cruz Biotechnology,
Santa Cruz, CA, USA; #SS319). Immunoblotting was carried out
with polyclonal anti-RIN1 (BD Transduction Laboratories),
monoclonal anti-phosphotyrosine 4G10 (Millipore, Billerica,
MA, USA; #05–321), polyclonal anti-ABL1 K-12 (Santa Cruz
Biotechnology) and monoclonal anti-b-tubulin (Sigma; #T6074).
Expression analysis in mouse cell lines required the use of
monoclonal and polyclonal antibodies speciﬁc for mRin1.
28
Immunohistochemical staining was similarly performed with
monoclonal antibody speciﬁc for mRin1 (VECTASTAIN ABC
System; VectorLabs, Burlingame, CA, USA). To reduce back-
ground from the mouse-derived anti-mRin1, we used the Vector
M.O.M. Basic Kit (BMK-2202) that contains a nonspeciﬁc
blocking solution to block endogenous mouse immunoglobulin.
Bone marrow transplantation and ﬂow cytometric
analysis and sorting
For engraftment assays, 8- to 12-week-old SJL mice (CD45.1)
were lethally irradiated (1100rads) before receiving 1 10
6
bone marrow cells from 8- to 12-week-old WT or Rin1
 / 
C57BL/6 mice (CD45.2). After 34 or 105 days, single-cell
suspensions were prepared from bone marrow, spleen and
thymus of euthanized recipient mice. Nucleated cells were
identiﬁed using Turk’s stain. Flow cytometric analysis was
performed on a FACSCanto (BD Biosciences) using Diva v6.1.1
and 1 10
6 cells per sample. Surface marker staining was
determined as a percentage of live cells (7AAD excluded). An
isoform-speciﬁc antibody to CD45.2
þ was used to identify
donor cells.
34 WT mice were obtained from Jackson Labs (Bar
Harbor, ME, USA) (SJL) and Charles River (WIlmington, MA,
USA) (C57BL/6).
The markers used to sort and deﬁne bone marrow cell sub-
populations for comparative Rin1 expression (Figure 2) are as
follows: Pre-B¼surface IgM negative, CD19 positive, B220
positive, CD43 negative; Pro-B¼IgM negative, CD19 positive,
B220 positive, CD43 positive; CLP¼lineage negative, Kit dimly
positive, Sca-1 dimly positive, interleukin 7R a-positive.
Results
BCR-ABL1 activity is increased by RIN1
Because RIN1 stimulates tyrosine kinase activity by binding
to the ABL SH3 and SH2 autoinhibitory domains,
27,28 and these
domains are consistently present in human leukemogenic ABL
fusion proteins (Figure 1a), we asked whether overexpression of
RIN1 could enhance BCR-ABL1 kinase activity. K562 cells,
which are derived from a BCR-ABL1-positive CML patient
sample, were transduced with a RIN1 lentivirus or a control
vector. The RIN1 overexpressing K562 cells had elevated levels
of total cellular tyrosine phosphorylation, consistent with higher
BCR-ABL1 kinase activity, when compared with vector
control cells (Figure 1b, left two lanes). Note that RIN1, itself
an ABL substrate, appears on the phosphotyrosine immunoblot
near the 95kDa marker. There was no change in the level of
BCR-ABL1 protein in K562 cells overexpressing RIN1
(Figure 1c), indicating that activation of existing BCR-ABL1
was responsible for the observed increase in cellular tyrosine
phosphorylation.
We next examined tyrosine phosphorylation of a speciﬁc
BCR-ABL1 substrate. CRKL is a well-characterized target of
ABL1, ABL2 and BCR-ABL1. Indeed, CRKL phosphorylation is
used as an indicator of BCR-ABL1 activity in patient-derived
CML cells.
5 We observed an elevation of CRKL tyrosine
phosphorylation levels in RIN1-transduced K562 cells com-
pared with vector control cells (Figure 1d). These results
emphasize that, although it is constitutively active relative to
ABL1, the BCR-ABL1 oncogene is still responsive to the
physiological regulator RIN1. Elevated kinase activity likely
accounts, at least in part, for the enhancement of BCR-ABL1-
mediated transformation and leukemogenesis by RIN1.
The ABL inhibitor imatinib works by binding to and stabilizing
an inactive conformation of the kinase domain.
35 We therefore
tested whether RIN1, which our model predicts should induce
an active conformation, might enhance catalytic activity even
in the presence of this kinase inhibitor drug. The levels of
total cellular phosphotyrosine remained elevated in RIN1
overexpression cells compared with control cells across a wide
range of imatinib concentrations (Figure 1b), suggesting that
enhancement of endogenous BCR-ABL1 kinase activity by RIN1
continues in the presence of imatinib. The persistence of higher
tyrosine phosphorylation levels in the RIN1 overexpression
K562 cells also correlated with resistance to long-term culture in
imatinib (Supplementary Figure S1). This modest effect may
reﬂect other changes, however, and its relevance to in vivo
resistance has not been validated.
RIN1 is expressed in hematopoietic cells but is not
needed for lineage development or engraftment
The mRin1 gene is expressed most highly not only in brain but
also in other tissues.
36 We detected Rin1 in murine hemato-
poietic cell lines 32D (myeloid) and BaF3 (lymphoid; pro-B)
(Figure 2a), as well as in spleen and thymus, tissues that are rich
in lymphoid cells (Figure 2b). Examination of thymus tissue
showed Rin1 expression throughout the T-cell-rich medullary
and cortical regions (Figure 2c). Rin1 was also observed in
sorted populations of common lymphoid progenitor cells as well
as in pro- and pre-B cells (Figure 2d). Rin1
 /  mutant mice
develop normally, however, with cell types and tissues that
would otherwise express Rin1 appearing unchanged.
37 When
bone marrow cells from WT and matched Rin1
 /  mice were
examined in more detail using multimarker FACS analysis, no
signiﬁcant changes in lineage composition were uncovered
(data not shown). This result suggests that, although some
aspects of Ras signaling contribute to hematopoietic differentia-
tion,
38 the Ras effector Rin1 is not required for normal
development in these lineages. Cultured Rin1
 /  bone marrow
cells also proliferated at the same rate as WT cells in response
to interleukin 7 and macrophage colony-stimulating factor
(data not shown), demonstrating that Rin1
 /  bone marrow
cells remain responsive to these physiological factors.
The surface marker and growth factor response analyses
suggested that Rin1 is unnecessary for lineage development.
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LeukemiaHowever, alterations in hematopoietic stem or progenitor cells
may have been undetectable with these methods. We next
engrafted bone marrow from WT or Rin1
 /  donors (CD45.2)
into lethally irradiated recipients (CD45.1). At 34 and 105 days
post transplantation, hematopoietic compartments (bone
marrow, spleen and thymus) were isolated from recipient mice
and examined for lineage composition. Similar proﬁles were
observed for both genotypes at both time points (Table 1),
suggesting that Rin1 is dispensable for the regeneration of a
complete hematopoietic system.
Previous studies showed that Rin1
 /  neurons and epithelial
cells exhibit conditional (for example, stimulation and stress
dependent) phenotypes.
28,37 We therefore considered whether
Rin1
 /  bone marrow cells might be compromised in their
response to oncogenic forms of ABL1.
RIN1 is required for transformation by BCR-ABL1 and
ETV6-ABL1
BCR-ABL1 transforms primary bone marrow cells, and this
leads to measurable growth factor-independent proliferation
in vitro.
31 To test whether RIN1 is required for transformation,
the p210 isoform of BCR-ABL1, which is common in CML, was
introduced by retroviral transduction into primary bone marrow
cells from WT or Rin1
 /  mutant mice. Cells were then cultured
Figure 1 BCR-ABL1 kinase activity in K562 cells is increased by RIN1. (a) Linear representation of ABL1 (top), translocation-derived human ABL1
and ABL2 fusion oncoproteins (middle six entries) and murine retroviral v-Abl (bottom). Src homology domains (SH2 and SH3) and tyrosine kinase
(TK) domains are indicated. BCR-ABL1
a represents the p190 isoform associated predominantly with ALL; BCR-ABL1
b represents the p210 isoform
associated predominantly with CML. (b) K562 cells transduced with vector (V) or RIN1 expression lentivirus (R) were treated with imatinib for
30min at the indicated concentration and analyzed by immunoblot with anti-phosphotyrosine (MW markers inkDa at left). The B95kDa band
that intensiﬁes in the R sample is most likely RIN1. b-tubulin (TUBB) immunoblot was used for normalization. (c) Levels of BCR-ABL1 (210kDa)
expression were evaluated by anti-ABL1 immunoblot of control (vector) and RIN1 overexpression (RIN1) K562 cells (ABL1 migrates below this
region). RIN1 immunoblot showed B8- to 10-fold overexpression above endogenous levels. TUBB immunoblot was used to normalize extracts.
(d) Tyrosine-phosphorylated endogenous CRKL (pY-CRKL) evaluated by immunoprecipitation with anti-CRKL and immunoblot with
anti-phosphotyrosine (top) or anti-CRKL (bottom).
Table 1 Engraftment of Rin1
 /  bone marrow cells
Antibody (lineage) Day 34 Day 105
Wild type
(%)
Rin1
 / 
(%)
Wild type
(%)
Rin1
 / 
(%)
Bone marrow
CD19 (B cell) 18 15 26 25
CD11b (mac/gran) 26 25 42 41
Ter119 (erythroid) 14 16 22 27
Spleen
CD19 (B cell) 50 52 73 72
CD11b (mac/gran) 4 4 5 4
CD3e CD4 (helper T) 6 4 7 15
CD3e CD8 (cytotoxic T) 3 2 8 6
Thymus
CD4
+ CD8
  (mature T) 9 9 6 10
CD4
  CD8
+ (mature T) 3 3 7 6
CD4
+ CD8
+ (immature T) 80 81 82 82
CD4
  CD8
  (immature T) 2 2 5 3
CD45.2 wild type or Rin1
 /  bone marrow samples were transplanted
into lethally irradiated CD45.1 mice. After 34 or 105 days, ﬂow
cytometric analysis was performed on bone marrow, spleen and
thymus cell suspensions. Data are presented as the percentage of
single live donor cells (CD45.2+; 7AAD excluded).
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Leukemiain the absence of growth factors and periodically counted.
Rin1
 /  cells showed much less expansion than WT cells in
these assays (Figure 3a), but grew equally well in the presence of
growth factors (data not shown). This suggested that the growth
factor independence normally conferred by BCR-ABL1
31 is to a
large degree dependent on the presence of RIN1. Similar results
were seen when using the ETV6-ABL1 oncogene (Figure 3b),
indicating that the need for RIN1 is associated with the ABL
tyrosine kinase rather than with the upstream fusion partner.
To determine whether RIN1 is required cell autonomously for
ABL-mediated transformation, we transduced bone marrow
cells with BCR-ABL1 and RIN1. For these experiments, we
used the ABL-binding domain of RIN1 (RIN1
ABD). This fragment,
similar to full-length RIN1, can enhance cell transformation
by BCR-ABL1.
29 Reconstitution of RIN1 expression restored
BCR-ABL1-mediated transformation of Rin1
 /  cells (Figure 3c).
RIN1 and RIN1
ABD have no transforming activity on their own
in this assay;
29 hence, the recovery of transforming potential
can be attributed to the restored collaboration of RIN1 and
BCR-ABL1. As a further control, we used a RIN1 mutant with
multiple tyrosine-to-phenylalanine substitutions that severely
compromise ABL binding and activation.
28,30 The mutant was
unable to rescue Rin1
 /  bone marrow cells for transformation
by BCR-ABL1 (Figure 3d). Taken together, these results support
a direct and obligate role for RIN1 in the transformation of
primary bone marrow cells by BCR-ABL1.
BCR-ABL1-transduced bone marrow cells from WT and
Rin1
 /  donors were also examined in transplantation experi-
ments. We observed no striking differences in the penetrance or
intensity of disease in models of lymphoid
29 or myeloid
39
leukemia (Supplementary Figure S2). The absence of a dramatic
reduction in leukemogenesis comparable to that seen in growth
factor independence assays of cultured bone marrow cells may
reﬂect a richer growth environment and longer time frame for
the in vivo experiments.
v-Abl does not require derepression by RIN1 for cell
transformation
The murine v-Abl oncogene arises from the fusion of a retroviral
Gag gene and cellular Abl1 sequences. Unlike human ABL
fusion oncoproteins, v-Abl does not include the autoinhibitory
SH3 domain
40 (Figure 1a). As a consequence, v-Abl is a more
active tyrosine kinase and a more potent transforming gene than
BCR-ABL1.
26 Rin1
 /  bone marrow cells were transformed to
growth factor independence by v-Abl as efﬁciently as WT bone
marrow cells (Figure 3e), indicating that an ABL oncoprotein
unhindered by SH3 domain autoinhibition does not require
RIN1 binding. Although v-Abl differs from BCR-ABL1 in other
ways, this result is consistent with RIN1 functioning through
derepression of the ABL SH3 domain to promote transformation.
The kinase inhibitor-resistant BCR-ABL1
T315I mutant
still requires RIN1
We next asked whether RIN1 was required by a multidrug-
resistant BCR-ABL1 mutation observed in CML patients. An
otherwise normal (non-fusion) ABL1 kinase with the T315I
kinase domain ‘gatekeeper’ mutation is still responsive to
RIN1,
27 suggesting that this mutation does not alter RIN1
binding and subsequent kinase derepression. Indeed, although
WT bone marrow cells transduced with BCR-ABL1
T315I proli-
ferated well, equivalent Rin1
 /  bone marrow cells transduced
with the same BCR-ABL1
T315I virus were not transformed
(Figure 3f). This provides further evidence that BCR-ABL1 is
reliant on RIN1 for relief of autoinhibition and perhaps for
additional contributions to signal-transduction pathways
required for transformation. This result also demonstrates that
regulation by RIN1 is independent of ABL active site alterations
conferring resistance to kinase inhibitors, and strongly suggests
Figure 2 Endogenous mouse Rin1 expression. (a) Left: Immunoblot
(IB) of Rin1 in 32D and BaF3 cells. Right: IB of wild-type (wt) and
Rin1
 /  ( / ) brain (br) tissue conﬁrming antibody speciﬁcity.
b-tubulin (Tubb) control below each blot. (b) IB of immunoprecipi-
tated (IP) material from spleen (sp) and thymus (th) tissue of wt and
Rin1
 /  mice. Arrow indicates Rin1. Asterisk marks background band.
ma, monoclonal antibody; pa, polyclonal antibody. (c) Immuno-
histochemical stain of Rin1 in mouse thymus. Top two panels show
wild-type thymus probed with anti-Rin1 and counter stained with
hematoxylin (left,  4; right,  10). Bottom left panel shows wild-type
control without anti-Rin1. Bottom right panel shows Rin1
 /  thymus
control. (d) IB of Rin1 in PreB, ProB and common lymphoid progenitor
(CLP) cells. Gapdh control below.
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Leukemiathat drug-resistant BCR-ABL1 mutants may be susceptible to
blockade of RIN1 association.
RIN1 directly regulates drug response in human
leukemia cells
We next turned to cell lines originating from human leukemias
with BCR-ABL1 oncogenes for additional insight into the role of
RIN1. RIN1 was detected in multiple BCR-ABL1-positive
myeloid leukemia lines (KCL22, JURL-MK1 and K562) and
B-cell lineage leukemia cell lines (BV173, TOM-1 and SUP-B15)
(Figure 4a). RIN1 was not detected by immunoblot in three other
CML lines (LAMA-84, KU-812 and KY01). We found a
suggestive association between RIN1 expression and imatinib
sensitivity (Supplementary Figure S3); the three lines with
undetectable RIN1 were the most sensitive to imatinib
Figure 3 Rin1 is required for transformation of primary bone marrow (BM) cells to growth factor independence. (a) BM cells from wild-type or
Rin1
 /  mice were infected with a BCR-ABL1 (p210) retrovirus, cultured without growth factors and counted at indicated times. (b) BM cell
transformation as in ‘a’, except using ETV6-ABL1 (a.k.a. TEL-ABL) retrovirus. (c) BM cell transformation as in ‘a’, except using virus expressing
both BCR-ABL1 and RIN1
ABD.( d) BM cell transformation as in ‘c’, except using a mutant (RIN1
ABDmut) that does not bind ABL1. (e)B M
cell transformation as in ‘a’, except using v-Abl retrovirus. (f) BM cell transformation as in ‘a’, except using the multidrug-resistant mutant
BCR-ABL1
T315I. All results are for duplicate samples counted in triplicate. Bars show standard deviation; * indicates Po0.05 between wt and
Rin1
 / . Panel f shows 14-day sample P¼0.06 between wt and Rin1
 / .
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Leukemia(Supplementary Figures S3A–C and H), although KCL22 had the
highest RIN1 level and was the least sensitive (Supplementary
Figures S3G and H). Further analysis with more leukemia cell
samples and more precise drug response data will be needed to
validate the signiﬁcance of this correlation, which does not
account for factors such as drug efﬂux rates.
Given the unique nature of each established leukemia cell
line, we chose to directly evaluate the contribution of RIN1 to
BCR-ABL1 function in several lines. Constitutive knockdown
of RIN1 expression using shRNA altered the total phospho-
tyrosine patterns in TOM-1, KCL22 and K562 cells (Figure 4b).
Although many phosphoproteins appeared unaffected,
numerous bands were weaker in the RIN1 knockdown cell
lines. No change was detected in the amount of BCR-ABL1,
consistent with a reduction in enzyme activity as an explanation
for the primarily diminished cellular phosphotyrosine proﬁle.
The few band intensity increases in K562 cells may reﬂect
enhanced kinases or repressed phosphatases downstream of
BCR-ABL1.
We reasoned that the loss of RIN1 might reduce the stability
of the active BCR-ABL1 kinase conformation, and render these
leukemia cells more susceptible to an ABL kinase inhibitor that
preferentially binds the inactive conformation. Silencing RIN1
expression in TOM-1
41 cells markedly increased sensitivity
to 8mM imatinib (Figure 5a), a concentration selected as
moderately cytotoxic to this ALL line. This result suggested that
the loss of RIN1 can synergize with standard kinase inhibitors to
block oncogenic ABL kinases. The viability and proliferation
rate of TOM-1 cells with the RIN1-targeted shRNA showed no
signiﬁcant difference from TOM-1 cells with the scrambled
shRNA control (Supplementary Figure S4A), perhaps because
silencing was less than complete or because these established
leukemia cell lines have been selected for additional mutations
that promote vigorous growth in culture. To rule out off-target
effects, the stable RIN1 knockdown TOM-1 cell line was
transduced with a murine Rin1 cDNA that is resistant to human
RIN1-targeted shRNA (data not shown). Ectopic Rin1 rescued
imatinib resistance (Figure 5b). Consistent with restored
BCR-ABL1 activity, expression of murine Rin1 also reversed
most of the phosphotyrosine signal suppression in RIN1 kd
TOM-1 cells (Figure 5c).
Primary pre-B ALL cells from the bone marrow biopsy of a
38-year-old male patient were used next to evaluate the
translational relevance of RIN1-targeted silencing. These cells
were collected from a relapse leukemia and carry the p210 form
of BCR-ABL1 with a T315I mutation, which confers imatinib
resistance. RIN1 knockdown reduced the intensity of the
cellular phosphotyrosine signal (Figure 4b) and enhanced
imatinib sensitivity (Figure 5d), without altering the baseline
proliferation rate of the cells (Supplementary Figure S4C). These
ﬁndings support and extend the conclusion that a direct ABL
activator, RIN1, controls the set point for imatinib sensitivity,
even in cells expressing the normally refractory BCR-ABL1
T315I
allele. They also imply that RIN1 silencing or inhibition might
Figure 4 Analysis of human leukemia cells. (a) Panel of CML and ALL cell lines immunoblotted with anti-ABL1 (top), anti-RIN1 (middle)
or anti-TUBB (bottom). CML cells (1¼KCL22; 2¼JURL-MK1; 3¼K562) and a B lymphoid CML blast crisis cell line (4¼BV173) express the p210
form of BCR-ABL, whereas ALL-derived cells (5¼TOM-1; 6¼SUP-B15) express the p190 form (arrowheads). Full-length RIN1 is marked with an
arrow (faster migrating bands may be alternately spliced isoforms). (b) TOM-1, KCL22, K562 and primary pre-B-ALL cells infected with control (ctr)
or RIN1-directed (kd) shRNA were analyzed by immunoblot with anti-phosphotyrosine. MW (kDa) markers are at left, arrowheads mark bands
most clearly reduced by RIN1 silencing. Lower panels show immunoblots for TUBB, RIN1 and BCR-ABL1.
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Leukemiacollaborate with a direct kinase inhibitor to overcome the
leukemogenic properties of ABL fusion proteins.
Discussion
Translocations that create BCR-ABL1 and other human leuke-
mogenic ABL gene fusions consistently retain the ABL SH3 and
SH2 domains, despite the fact that biochemical and structure
data have established that these domains restrain kinase activity.
Our data suggest that RIN1 binding to ABL SH3 and SH2
domains stabilizes the active conformation of the kinase,
enhancing the already constitutive activity of the fusion protein
(Figure 6). The result is increased cellular tyrosine phosphoryla-
tion and transforming activity in the presence of RIN1, which
comports with the observed overexpression of RIN1 in some
leukemias
42 and lymphomas.
43 RIN1 loss greatly reduced the
ability of ABL1 fusions to establish a transformed phenotype in
bone marrow cells, consistent with a cell autonomous require-
ment for RIN1 to unleash the full potential of ABL tyrosine
kinases. Even BCR-ABL
T315I, a drug-resistant mutant with
increased transformation potency,
44 was dependent on RIN1
for bone marrow cell transformation. However, we did not
detect any signiﬁcant effects of Rin1 deletion on leukemogenesis
by BCR-ABL1-transduced bone marrow cells in mouse trans-
plantation model systems. These data suggest an important
supporting role for RIN1 in BCR-ABL1-mediated transformation,
but do not fully resolve the contribution of RIN1 in spontaneous
leukemias.
The absence of an SH3 domain in murine v-Abl (Gag-Abl1)
increases its constitutive kinase activity and makes it a highly
potent oncogene. Deletion of the autoinhibitory SH3 domain is
likely to be more strongly activating than derepression by
binding to endogenous RIN1. However, although an SH3
deletion mutant of BCR-ABL1 does potently transform cells
in vitro and produces myeloproliferative disorders in a xenograft
model,
45 it does not possess full leukemogenic potential.
46
There are also signiﬁcant differences in the types of leukemias
induced by v-Abl versus BCR-ABL1.
47 Together with the fact
that oncogenic fusions disrupting the ABL1 SH3 domain are
extremely rare in human leukemias,
24 it seems likely that
the ABL SH3 domain is retained through selective pressure
because it contributes to leukemogenesis and/or to leukemia
progression in vivo. Additional evidence for this model comes
from studies demonstrating that transphosphorylation of BCR-
ABL1 SH3 and SH2 domain tyrosines modulates transforming
activity.
48 RIN1 likely functions, in part, to elevate ABL tyrosine
kinase activity above a transformation threshold level while
Figure 5 RIN1 silencing sensitizes ALL cells to imatinib. (a) Control (ctr) and RIN1-silenced (kd) TOM-1 cells (1 10
4/ml) were cultured in 8mM
imatinib for the indicated time. Cell counts normalized to 2d-ctr. (b) Control (ctr), RIN1 knockdown (RIN1 kd) and knockdown rescued with mouse
Rin1 (RIN1 kdþmRin1) TOM-1 cells were cultured in 8mM imatinib for 9 days. (c) Control, RIN1 kd and RIN1 kdþmRin1 TOM-1 cells were
immunoblotted with anti-phosphotyrosine. TUBB and RIN1 immunoblots are shown below. Murine Rin1 and human RIN1 were detected using
different antibodies. Note: hRIN1 bands are from the same exposure of a single immunoblot. (d) Control (ctr) and RIN1-silenced (kd) B-ALL cells
were cultured in 10mM imatinib for the indicated time. Cell viability was determined by propidium iodide stain and ﬂow cytometry. Panels a, b and
d: s.d. from triplicate samples counted in duplicate; * indicates Po0.05 between control and knockdown.
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Leukemiaallowing the SH3 domain to enhance leukemia progression
through other mechanisms. RIN1 might additionally contribute
to oncogenic ABL signaling by inﬂuencing substrate speciﬁcity,
directing subcellular distribution of ABL fusion proteins or
recruiting signaling partners that promote expansion of the
leukemic cell population. An alternative explanation
for consistent SH3 domain retention is strong preference for
recombination in the ﬁrst ABL1 intron. This is unlikely given the
evidence cited and because all oncogenic ABL2 fusions show
the same breakpoint (in this case between exons 2 and 3).
As BCR-ABL1 is required to maintain cell transformation, a
phenomenon described as ‘oncogene addiction’, RIN1 silencing
alone might be expected to impair tumor cell proliferation.
Although reduced RIN1 expression did not arrest TOM-1 or
LAX2 cells in our experiments, it did signiﬁcantly heighten the
sensitivity of these cells to imatinib. This enhanced drug
responsiveness may result from a shift toward the inactive
ABL1 kinase conformation that imatinib preferentially binds and
stabilizes,
35 and away from the active kinase conformation that
RIN1 preferentially binds and stabilizes
27 (Figure 6). Conforma-
tion stabilization does not imply protein stabilization, and we
observed no indication that altered RIN1 levels affect BCR-ABL1
protein levels. The drug-sensitizing effect of RIN1 silencing
suggests that disruption of RIN1 binding might synergize with
kinase inhibitors to signiﬁcantly expand the range of leukemias
that respond to these drugs. We note that some BCR-ABL1-
positive leukemia cell lines had relatively low RIN1 levels. RIN1
may nevertheless be important in those cells for BCR-ABL1
activity and transformation. Alternatively, low RIN1 expression
may indicate additional genetic alterations, occurring in vivo or
in culture, that confer a degree of independence from RIN1.
In epithelial cells, RIN1 has a role in plasma membrane
receptor internalization and cell motility through the coordi-
nated activation of RAB5 GTPases that regulate endocytosis and
ABL tyrosine kinases that regulate actin remodeling.
28,49 In solid
tumors, RIN1 is a tumor suppressor in breast cancer,
50 but a
tumor enhancer in non-small-cell lung cancer.
51 In both cases,
the main contribution of RIN1 appears to be through RAB5
activation and growth factor receptor trafﬁcking. The rescue of
Rin1
 /  bone marrow cell transformation by a RIN1 amino
terminal fragment with no RAB5-GEF domain, however,
demonstrates that RAB5 activation is not required for collabora-
tion with BCR-ABL1. The apparently contradictory roles for
RIN1 as a myeloproliferative disorder enhancer and epithelial
carcinoma suppressor (in breast cancer) are perhaps not
surprising given the differences between these diseases and
their cells of origin. Neither is it unprecedented; NOTCH1 gain
of function is associated with T-cell leukemias,
52 whereas
NOTCH1 silencing contributes to the progression of cervical
cancers.
53
RIN1 silencing reduced BCR-ABL1 activity while enhancing
imatinib sensitivity in established and primary leukemia cells,
possibly the result of a shift toward the inactive ABL conformation.
Mutations in the SH3-SH2 domains of BCR-ABL1 can also reduce
imatinib sensitivity,
54,55 perhaps by overriding the dependence on
RIN1 binding. Importantly, the only such mutations validated to
confer imatinib sensitivity in patient samples never occurred
simultaneously with kinase domain mutations.
55 This suggests the
potential value of small molecule inhibitors that target the
functional interaction of RIN1 and BCR-ABL1 through direct
binding blockade or allosteric interference. Such drugs might be
combined with kinase active site-directed inhibitors for a ﬁrst-line
therapy that reduces relapse rates by requiring the simultaneous
acquisition of independent resistance mutations.
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